UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 279

Sortiert nach

A review of trabectedin (ET-743): a unique mechanism of action

Molecular cancer therapeutics, 2010-08, Vol.9 (8), p.2157-2163

2010

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers

Molecular cancer therapeutics, 2017-10, Vol.16 (10), p.2130-2143

2017

Link zum Volltext

Verfügbarkeit prüfen

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling

Molecular cancer therapeutics, 2017-08, Vol.16 (8), p.1623-1633

2017

Link zum Volltext

Verfügbarkeit prüfen

The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma

Molecular cancer therapeutics, 2017-06, Vol.16 (6), p.1002-1009

2017

Link zum Volltext

Verfügbarkeit prüfen

KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer

Molecular cancer therapeutics, 2018-09, Vol.17 (9), p.1973-1983

2018

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer

Molecular cancer therapeutics, 2015-11, Vol.14 (11), p.2433-2440

2015

Link zum Volltext

Verfügbarkeit prüfen

Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR -Mutated Non-Small Cell Lung Cancer

Molecular cancer therapeutics, 2018-04, Vol.17 (4), p.740-750

2018

Link zum Volltext

Verfügbarkeit prüfen

Mechanistic basis for overcoming platinum resistance using copper chelating agents

Molecular cancer therapeutics, 2012-11, Vol.11 (11), p.2483-2494

2012

Link zum Volltext

Verfügbarkeit prüfen

The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells

Molecular cancer therapeutics, 2012-03, Vol.11 (3), p.604-615

2012

Link zum Volltext

Verfügbarkeit prüfen

Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers

Molecular cancer therapeutics, 2012-10, Vol.11 (10), p.2105-2115

2012

Link zum Volltext

Verfügbarkeit prüfen

Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212

Molecular cancer therapeutics, 2012-03, Vol.11 (3), p.720-729

2012

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy dosing schedule influences drug resistance development in ovarian cancer

Molecular cancer therapeutics, 2011-07, Vol.10 (7), p.1289-1299

2011

Link zum Volltext

Verfügbarkeit prüfen

Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity

Molecular cancer therapeutics, 2015-11, Vol.14 (11), p.2613-2622

2015

Link zum Volltext

Verfügbarkeit prüfen

A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats

Molecular cancer therapeutics, 2006-07, Vol.5 (7), p.1710-1722

2006

Link zum Volltext

Verfügbarkeit prüfen

The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression

Molecular cancer therapeutics, 2015-06, Vol.14 (6), p.1354-1364

2015

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms of Resistance to Antibody-Drug Conjugates

Molecular cancer therapeutics, 2016-12, Vol.15 (12), p.2825-2834

2016

Link zum Volltext

Verfügbarkeit prüfen

Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2

Molecular cancer therapeutics, 2009-03, Vol.8 (3), p.665-671

2009

Link zum Volltext

Verfügbarkeit prüfen

The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells

Molecular cancer therapeutics, 2011-12, Vol.10 (12), p.2373-2383

2011

Link zum Volltext

Verfügbarkeit prüfen

A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax)

Molecular cancer therapeutics, 2010-11, Vol.9 (11), p.2943-2950

2010

Link zum Volltext

Verfügbarkeit prüfen

AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer

Molecular cancer therapeutics, 2019-10, Vol.18 (10), p.1875-1886

2019

Link zum Volltext

Verfügbarkeit prüfen

The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance

Molecular cancer therapeutics, 2018-09, Vol.17 (9), p.2004-2012

2018

Link zum Volltext

Verfügbarkeit prüfen

Sodium butyrate inhibits the self-renewal capacity of endometrial tumor side-population cells by inducing a DNA damage response

Molecular cancer therapeutics, 2011-08, Vol.10 (8), p.1430-1439

2011

Link zum Volltext

Verfügbarkeit prüfen

The determinants of sensitivity and acquired resistance to gemcitabine differ in non–small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity

Molecular cancer therapeutics, 2006-07, Vol.5 (7), p.1800-1806

2006

Link zum Volltext

Verfügbarkeit prüfen

Expression and silencing of the microtubule-associated protein Tau in breast cancer cells

Molecular cancer therapeutics, 2010-11, Vol.9 (11), p.2970-2981

2010

Link zum Volltext

Verfügbarkeit prüfen

Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer

Molecular cancer therapeutics, 2010-12, Vol.9 (12), p.3186-3199

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 279

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

ThemaDrug Resistance

Zeitschrift / SerieMolecular Cancer Therapeutics

ThemaCancer Research

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(279)
Mit Volltextzugriff
(279)

Publikationsform

Artikel
(279)

Sprache

Englisch
(279)
Japanisch
(278)

Erscheinungsjahr

n.n

Thema

Oncology
(279)
Life Sciences & Biomedicine
(272)
Science & Technology
(272)
Humans
(268)
Cell Line, Tumor
(202)
Animals
(153)
Mice
(120)
Drug Resistance, Neoplasm
(112)
Antineoplastic Agents - Pharmacology
(110)
Drug Resistance, Neoplasm - Genetics
(101)
Female
(94)
Xenograft Model Antitumor Assays
(92)
Drug Resistance, Neoplasm - Drug Effects
(83)
Apoptosis - Drug Effects
(64)
Cell Proliferation - Drug Effects
(60)
Gene Expression Regulation, Neoplastic - Drug Effects
(50)
Protein Kinase Inhibitors - Pharmacology
(50)
Male
(48)
Cell Survival - Drug Effects
(47)

14 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(279)
Electronic Journals Library - Freely accessible e-journals
(279)

Zeitschrift / Serie

Mol. Cancer Ther
(1)

Menü

Weitere Dienste

Einstellungen

A review of trabectedin (ET-743): a unique mechanism of action

Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling

The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma

KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer

Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer

Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR -Mutated Non-Small Cell Lung Cancer

Mechanistic basis for overcoming platinum resistance using copper chelating agents

The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells

Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers

Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212

Chemotherapy dosing schedule influences drug resistance development in ovarian cancer

Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity

A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats

The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression

Mechanisms of Resistance to Antibody-Drug Conjugates

Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2

The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells

A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax)

AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer

The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance

Sodium butyrate inhibits the self-renewal capacity of endometrial tumor side-population cells by inducing a DNA damage response

The determinants of sensitivity and acquired resistance to gemcitabine differ in non–small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity

Expression and silencing of the microtubule-associated protein Tau in breast cancer cells

Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer

Aktive Filter

Suchergebnisse filtern